Drug-induced liver injury with cholestasis. Part 1: focus on drugs for the treatment of cardiovascular diseases and hypoglycemic drugs


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The number of cases of drug-induced liver damage (DILI) is about 10% of all adverse drug reactions (ADRs). Cholestatic variant accounts for 20% to 40% of all DILIs. The development of this type of ADRs is associated with use of many classes of drugs, among which, special attention is payed to drugs for the treatment of the cardiovascular system (antiarrhythmics, antihypertensive drugs, anticoagulants, antiplatelet agents, etc.) due to their frequent use in clinical practice. The mechanism of liver damage includes immune-mediated, allergic and idiosyncratic reactions. Alertness of practical health care professionals regarding the potential hepatotoxic effect of drugs and its timely diagnosis will improve the safety and prognosis of patients receiving treatment for cardiovascular diseases.

Full Text

Restricted Access

About the authors

O. D Ostroumova

Russian Medical Academy of Continuous Professional Education

A. P Pereverzev

Russian Medical Academy of Continuous Professional Education

Email: acchirurg@mail.ru. terapia_polimorbid@rmapo.ru

E. E Pavleeva

A.I. Yevdokimov Moscow State University of Medicine and Dentistry

A. G Komarova

City Clinical Hospital n.a. S.P. Botkin of the Moscow Healthcare Department

References

  1. Ивашкин В.Т. Болезни печени и желчевыводящих путей. Руководство для врачей. 2-е изд. М., 2005. 536 с. [Ivashkin V.T. Diseases of the liver and biliary tract. A guide for doctors. 2 ed. M, 2005. 536p. (In Russ.)].
  2. Ивашкин В.Т. Болезни печени и желчевыводящих путей. Под ред. В.Т. Ивашкина. М., 2002. 416 с. [Ivashkin V.T. Diseases of the liver and biliary tract. Ed. by V.T. Ivashkin. M, 2002. 416p. (In Russ.)].
  3. Ostapowicz G, Fontana R.J., Schi0dt F.V, et al. Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States. Ann Intern Med. 2002;137(12): 947-54.
  4. Morales L.M., Velez N.L., Octavio German M.M. Hepatotoxicity: A Drug-Induced Cholestatic Pattern. Rev Col Gastroenterol. 2016; 31(1)34-45.
  5. Fontana R.J., Hayashi P.M., Gu J., et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterol. 2014;147(1):96-108.e4. doi: 10.1053/j.gastro.2014.03.045.
  6. Лазебник Л.Б., Голованова Е.В., Хлынова О.В. и др. Лекарственные поражения печени (ЛПП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2020;174(2):29-54. Doi: 10.31 1 46/1 682-8658-ecg-174-2-29-54. [Lazebnik L.B., Golovanova E.V, Xlynova O.V., et al. Medicinal liver damage (DIL) in adults. Eksperimental'naya i klinicheskaya gastroenterologiya. 2020;174(2):29-54. Doi: 10.31 1 46/1 682-8658-ecg-174-2-29-54. (In Russ.)].
  7. Галимова С.Ф. Лекарственные поражения печени (часть 1). Трансплантология. 2011;(1):13-21.
  8. Ивашкин В.Т., Барановский А.Ю., Райхель-сон К.Л. и др. Лекарственные поражения печени (клинические рекомендации для врачей). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(1):101 31. doi: 10.22416/1382-4376-2019-291-101-131
  9. Burt A.D., Portmann B.C., Ferrell L.D. MacSween's Pathology of the Liver, Sixth Edition, 2012. Р. 645-760
  10. Ortega-Alonso A., Stephens C., Lucena M.I., Andrade R.J. Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. Int J Mol Sci. 2016;17(5):714. doi: 10.3390/ijms17050714.
  11. Bhamidimarri K.R., Schiff E. Drug-induced cholestasis. Clin Liver Dis. 2013;17(4):519-vii. doi: 10.1016/j.cld.2013.07.015.
  12. Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol. 2008;14(44):6774-85. Doi: 10.3748/ wjg.14.6776.
  13. LiverTox®. Clinical and Research Information on Drug-Induced Liver Injury. Available at: https:// livertox.nih.gov/Phenotypes_lact.html (accessed 16.05.2020).
  14. Tisdale J.E., Miller D.A. Drug-Induced Diseases: Prevention, Detection, and Management. Am J Pharm Educ. 2018. 3rd ed.
  15. Edmonds M.E., Hayler A.M. A case of intra-hepatic cholestasis after disopyramide therapy. Eur J Clin Pharmacol. 1980;18(3):285-86. doi: 10.1007/BF00563013.
  16. La Brocca A. Tossicita epatica da propafenone: descrizione di un caso [Hepatic toxicity of propafenone: a case description]. Ann Ital Med Int. 2002;17(4):261-64.
  17. Russmann S., Niedrig D.F., Budmiger M., et al. Rivaroxaban postmarketing risk of liver injury J Hepatol. 2014;61(2):293-300. doi: 10.1016/j.jhep.2014.03.026.
  18. Lambert A, Cordeanu M., Gaertner S., et al. Rivaroxaban-induced liver injury: Results from a venous thromboembolism registry. Int J Cardiol. 2015;191:265-66. Doi: 10.1016/j. ijcard.2015.04.248.
  19. Aslan A.N, Sari C., Bastug S., et al. Severe jaundice due to intrahepatic cholestasis after initiating anticoagulation with rivaroxaban. Blood Coagul Fibrinolys. 2016;27(2):226-27. doi: 10.1097/MBC.0000000000000442.
  20. Chau T.N., Yim K.F., Mok N.S., et al. Clopidogrel-induced hepatotoxicity after percutaneous coronary stenting. Hong Kong Med J. 2005;11(5):414-16.
  21. Tabibian N, Alpert L., Alpert E. Captopril-induced liver dysfunction. South Med J. 1987;80(9):1173-75. doi: 10.1097/00007611-198708090-00023.
  22. Schattner A., Kozak N., Friedman J. Captopril-induced jaundice: report of 2 cases and a review of 13 additional reports in the literature. Am J Med Sci. 2001;322(4):236-40. doi: 10.1097/00000441-200110000-00016.
  23. Parker W.A. Captopril-induced cholestatic jaundice. Drug Intell Clin Pharm. 1984;18(3):234-35. doi: 10.1177/106002808401800309.
  24. Rahmat J., Gelfand R.L., Gelfand M.C., et al. Captopril-associated cholestatic jaundice. Ann Intern Med. 1985;102(1):56-8. doi: 10.7326/0003-4819-102-1-56.
  25. Todd P., Levison D., Farthing M.J. Enalapril-related cholestatic jaundice. J R Soc Med. 1990;93(4):27)-72.
  26. Valle R., Carrascosa M., Cillero L., Perez-Castrillon J.L. Enalapril-induced hepatotoxicity. Ann Pharmacother. 1993;-7(11):1405. doi: 10.1177/10600-80930-7011-0.
  27. da Silva G.H., Alves A.V., Duques P, et al. Acute hepatotoxicity caused by enalapril: a case report. J Gastrointestin Liver Dis. 2010;13(2):187-30.
  28. Yeung E., Wong F.S., Wanless I.R., et al. Ramipril-associated hepatotoxicity. Arch Pathol Lab Med. 2003;127(11):1493-97. doi: 10.1043/1543-2165(2003)127<1493:RH>2. 0.CO;2.
  29. Douros A., Kauffmann W., Bronder E., et al. Ramipril-induced liver injury: case report and review of the literature. Am J Hypertens. 2013;26(3):1070-75. doi: 10.1093/ajh/ hpt090.
  30. Nunes A.C., Amaro P, Mac as F, et al. Fosinopril-induced prolonged cholestatic jaundice and pruritus: first case report. Eur J Gastroenterol Hepatol. 2001;13(3):273-82. doi: 10.1097/0004-737--00103000-0001 1.
  31. Chou J.W., Yu C.J., Chuang PH., et al. Successful treatment of fosinopril-induced severe cholestatic jaundice with plasma exchange. Ann Pharmacother. 2008;42(12):1887-92. doi: 10.1345/aph.1L-9.
  32. Jeserich M., Ihling C., Allgaier H.P, et al. Acute liver failure due to enalapril. Herz. 2000;25(7):689-93. doi: 10.1007/pl00001983.
  33. Gonzalez de la Puente M.A., Calderon E., Espinosa R., et al. Fatal hepatotoxicity associated with enalapril. Ann Pharmacother. -001;35(11):149-.
  34. Romero-Gomez M., Miralles E.J., Garcia Diaz E., et al. Hepatotoxicity induced by fosinopril. J Hepatol. -001;35(-):309-10. Doi: 10.1016/ s0168-8278(01)00098-8.
  35. Jimenez-Saenz M., Arroyo Q., Sanjuan M., Herrerias J.M. Hepatitis colesta tica por candesartan. Reporte de un caso [Candesartan-induced cholestatic hepatitis: a case report]. Gastroenterol Hepatol. 2010;33(1):66-7. doi: 10.1016/j.gastrohep.-009.06.003.
  36. Hariraj R., Stoner E., Jader S., Preston D.M. Drug points: prolonged cholestasis associated with irbesartan. BMJ. -000;3-1(7-60):547. doi: 10.1136/bmj.3-1.7-60.547.
  37. Andrade R.J., Lucena M.I., Fernandez M.C., et al. Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. Eur J Gastroenterol Hepatol. 2002;14(8):887-90. doi: 10.1097/00042737-200208000-00014.
  38. Annicchiarico B.E., Siciliano M. Could irbesartan trigger autoimmune cholestatic hepatitis? Eur J Gastroenterol Hepatol. -005;17(-):-47-48. doi: 10.1097/0004-737--0050-000-00019.
  39. Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension [published correction appears in Eur Heart J. 2019 Feb 1;40(5):475]. Eur Heart J. 2018;33(33):3021-107. doi: 10.1093/eurheartj/ehy339.
  40. de Castro M.L., Hermo J.A., Baz A., et al. Hepatitis colestásica aguda tras la reintroducción de atorvastatina [Acute cholestatic hepatitis after atorvastatin reintroduction]. Gastroenterol Hepatol. 2006;29(1):2-24. doi: 10.1157/13083248
  41. Lata S., Chudy B. Ostre cholestatyczne zapalenie watroby wywofane przez simvastatyne u 67-letniego pacjenta [Acute cholestatic hepatitis caused by simvastatine in a 67-year-old patient]. Przegl Lek. 2006;63(Suppl. 7):97-8.
  42. Gershovich O.E., Lyman A.E. Jr. Liver function test abnormalities and pruritus in a patient treated with atorvastatin: case report and review of the literature. Pharmacother. 2004;24(1):150-54. Doi: 10.159-/phco.-4.1.150.34803.
  43. Merli M., Bragazzi M.C., Giubilo F., et al. Atorvastatin-induced prolonged cholestasis with bile duct damage. Clin Drug Investig. 2010;30(3):205-3. doi: 10.2165/11531660000000000-00000.
  44. Mach F., Baigent C., Catapano A.L., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. -0-0;41(1):111-88. doi: 10.1093/eurheartj/ ehz455.
  45. Stolk M.F., Becx M.C., Kuypers K.C.,Seldenrijk C.A. Severe hepatic side effects of ezetimibe. Clin Gastroenterol Hepatol. 2006;4(7):308-11. doi: 10.1016/j.cgh.-006.04.014.
  46. Bhardwaj S.S., Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis. -007;11(3):597-vii. doi: 10.1016/j.cld.-007.06.010.
  47. Ho C.Y., Kuo T.H., Chen T.S., et al. Fenofibrate-induced acute cholestatic hepatitis. J Chin Med Assoc. 2004;67(5):245-47.
  48. Hajdu D., Aiglova K., Vinklerova I., Urbanek K. Acute cholestatic hepatitis induced by fenofibrate. J Clin Pharm Ther. 2003;34(5):533-602. doi: 10.1111/j.1365-2710.2009.01029.x.
  49. Lepicard A, Mallat A, Zafrani E.S., Dhumeaux D. Atteinte chronique des canaux biliaires interlobulaires induite par le fenofibrate [Chronic lesion of the interlobular bile ducts induced by fenofibrate]. Gastroenterol Clin. Biol. 1994;18(11):1033-35.
  50. Andrade R.J., Lucena M.I., Kaplowitz N., et al. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatol. 2006;44(6):1581-88. doi: 10.1002/hep.21424.
  51. Kaplowitz N., DeLeve L.D., eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013. Dor. https://doi.org/10.1016/C2010-0-68917-6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies